Decision-making on FP 7 work programmes and calls

Decision-making on FP 7 work programmes and calls European Commission Research and Inovation DG, Directorate F Health Grigorij Kogan EKHA Meeting, Brussels 23/01/2012 3/16/2018 1

EU support for Research and Innovation 3/16/2018 The € 50 billion Seventh Framework Programme (FP 7, 2007 -2013) supports basic and applied research activities, still far from the market, offers money and concentrates resources on strategic research areas, always on the basis of technological and scientific excellence. The broad objectives of FP 7 have been grouped into four categories: Cooperation Ideas People Capacities For each type of objective, there is a specific programme corresponding to the main areas of EU research policy. All specific programmes work together to promote and encourage the creation of European poles of (scientific) excellence 2

FP 7 budget (2007 -2013): € 55 billion = ~6% of public R&D investment in Europe 3/16/2018 3

Cooperation programme: thematic areas (€ 32. 4 billion) 3/16/2018 4

http: //bookshop. europa. eu/eubookshop/publication. Details. action? pubuid=593335&offset=0 3/16/2018 5

FP 7 Health Programme - structure pillar 1: pillar 2: pillar 3: Biotechnology, generic tools & technologies for health Translating research for human health Optimising the delivery of health care cross-cutting issues: child health, the health of ageing population gender-related health issues Activity (Pillar) 4: Other actions across theme 3/16/2018 6

Collaborative research in the Health theme Main policy drivers: § Improving health of European citizens § Increasing competitiveness of European healthrelated industries and businesses § Addressing global health issues, including emerging epidemics 3/16/2018 7

Collaborative research at European level across borders and other barriers ● between countries: u multinational consortia, with at least 3 partners from 27 EU Member States (MS) and / or Associated Countries (AC) e. g. : Albania, Croatia, FYR Macedonia, Iceland, Israel, Liechtenstein, Montenegro, Norway, Serbia, Switzerland, Turkey. u researchers from any country in the world can participate, from industrialised countries and from developing countries. e. g. : Argentina, Australia, Brazil, Canada, China, India, Japan, Korea, New-Zealand, Russia, South-Africa, USA… ● between different types of organizations Public & private sector: universities, research centres, large companies, Small and medium-sized enterprises (SMEs), etc. ● between disciplines: multidisciplinary, translational 3/16/2018 8

Collaborative research in the Health theme 1: Biotechnology, generic tools and technologies Ø High-throughput research Ø Detection, diagnosis and monitoring Ø Predicting suitability, safety and efficacy of therapies Ø Innovative therapeutic approaches and interventions 3/16/2018 9

Collaborative research in the Health theme 2: Translating research for human health Ø Integrating biological data and processes: large-scale data gathering, systems biology Ø Research on the brain and related diseases, human development and ageing Ø Translational research in major infectious diseases Ø Translational research in other major diseases 3/16/2018 10

Collaborative research in the Health theme 3: Optimising the delivery of healthcare Ø Translating clinical research into clinical practice Ø Quality, efficiency and solidarity of healthcare systems Ø Enhanced health promotion and disease prevention 3/16/2018 11

Collaborative research in the Health theme 4. Actions across the Theme Ø Coordination & Support Actions across theme Ø Responding to EU policy needs Ø Specific International Cooperation Actions (SICAs) 3/16/2018 12

FP 7 Cooperation Work Programme: Health-2012 3/16/2018 13

Two-stage submission and evaluation procedure Timetable Publication of call FP 7 -HEALTH-2012 -INNOVATION-2 20 July 2011 Deadline for submission of stage 1 outline proposals 27 September 2011 Evaluation of stage 1 outline proposals October 2011 ESRs sent to outline proposal coordinators (“initial information letters”, including invitation letters to successful applicants) November 4, 2011 Deadline for submission of stage 2 full proposals 13 December 2011 Evaluation of stage 2 full proposals January 2012 Ethical screening By February 3, 2012 Invitation letter to successful coordinators to launch grant agreement negotiations with Commission services By February , 2012 Negotiation kick-off meeting in Brussels February 13, 2012 Signature of first grant agreements April 2012 3/16/2018 14

Funding schemes in the Health theme Funding schemes limits partners Large-scale integrating project (CP-IP) ≥ € 6 m ≤ € 12 m ≥ 3 Network of Excellence (No. E) ≤ € 12 m ≥ 3 Small- or medium-scale focussed research project (CP-FP) ≤ € 3 m or € 6 m ≥ 3 Coordination action (CA)* ≤ € 1. 5 m ≥ 3 Support action (SA)* ≤ € 0. 5 m ≥ 1 * for CAs and SAs there are some exceptions. 3/16/2018 15

Policy dimensions: Industry (SME) participation & International Cooperation Emphasis and special measures for: l Small & Medium-sized Enterprises (SMEs) è Opportunities and support measures l International Cooperation è the possibility to tackle issues on a global scale 3/16/2018 è an opportunity to extend networks beyond Europe 16

Who prepares the work programmes for the ● The EU Commission Research Priorities 3/16/2018 § Collects ideas for the preparation of the annual FP 7 work program § Drafts the (annual) FP 7 work plans § Within the EU Commission Scientific Officers (SO) are responsible for the preparatory work o Advisory Groups (AG) § Have been set up by the EU Commission for each of the FP 7 themes § They provide consistent, consolidated advice for the work program § Members sit on the AG in their personal capacity and do not represent any organisation or country o National Contact Points (NCPs) § Are main providers of advice and individual assistance in all Member States and Associated States § Have been set up by the Member or Associated States so the type and level of services offered may differ from country to country o Programme Committees (PCs) § Play an important role at the end of the preparation process of each work program. § They have to give their approval for all the work programmes that have been prepared by he EU Commission. § Are involved quite early in the preparation process to insure that the preparation procedure works quick and smooth 17

Scientific excellence at European level From policy to funding the best research projects: ● The policy for Health research is described in the FP 7 specific programme (available on CORDIS http: //cordis. europa. eu/home_en. html) ● Each year, a work programme is prepared by the EC, in consultation with a scientific Advisory Group and with the Programme Committee ● Through calls for proposals the EC invites researchers from all Europe and beyond to submit their proposals ● The very best projects are selected on the basis of evaluation by independent experts (peer review) ● After negotiation of a grant agreement, a project is funded for 25 years 3/16/2018 18

Submission & evaluation Basic principles: l annual calls for proposals l eligibility (scope, partners, funding limits, deadline) l evaluation by panels of independent experts è overseen by Independent Observers l 3 criteria: è Science & Technology excellence è Implementation & Management è Potential Impact l feedback: Evaluation Summary Reports (ESRs) 3/16/2018 19

Annual calls for proposals in the Health Theme Ø 1 st call (2007 budget): € 641 million Ø 2 nd call (2008 budget): € 577 million Ø Ø Ø 3 rd call (2009 budget): € 610 million 4 th call (2010 budget): € 660 million 5 th call (2011 budget): € 650 million 6 th call (2012 budget): ~ € 645 million 7 th call (2013 budget): ~ 3/16/2018 20

The Innovative Medicines Initiative (IMI): the Largest PPP in Life Sciences R&D http: //www. imi. europa. eu/ Why Public-Private Partnership? • Innovative medicines require in-depth knowledge of disease pathways and molecular targets • Anticipating potential side effects of new drugs is a must • The pharmaceutical industry builds new business models based on collaboration and transparency Key Concepts Underlying IMI Projects: • Pre-competitive research • Open innovation Four Calls published since 2008: • 23 projects funded • Over € 450 million committed 21 3/16/2018 21

Coverage of Kidney Diseases in FP 7 Pillar IDEAS – ERC (European Research Council): 4 projects with € 6, 813, 200 EU Contribution Pillar COOPERATION HEALTH: 7 projects with € 46, 188, 148 EU Contribution INFSO: 2 projects with € 8, 759, 140 EU Contribution Pillar PEOPLE – 13 projects with € 9, 872, 575 EU Contribution Total EU Contribution - € 71, 633, 063 3/16/2018 22

3/16/2018 23

Contacts & Information FP 7 Health web site: http: //cordis. europa. eu/fp 7/health NCPs: http: //cordis. europa. eu/fp 7/health/support_en. html Registration as an Expert: https: //cordis. europa. eu/emmfp 7/ FP 7 calls: http: //cordis. europa. eu/fp 7/dc Health projects database: www. healthcompetence. eu SMEsgo. Health: www. smesgohealth. org 3/16/2018 24

The Health Directorate Director – Dr. Ruxandra Draghia-Akli: Medical Research unit (F 2) Head of unit: Maria Vidal-Ragout (maria-jose. vidal-ragout@ec. europa. eu) Deputy Head of Unit: Karim Berkouk (karim. berkouk@ec. europa. eu) Infectious Diseases unit (F 3) Head of unit: Line Mathiessen (line. mathiessen@ec. europa. eu) Deputy Head of unit: Anna Lönnroth (anna. lonnroth@ec. europa. eu) Avanced Therapies and Systems Medicine unit (F 4) Head of unit: Arnd Hoeveler (arnd. hoeveler@ec. europa. eu) Deputy Head of unit: Bernard Mulligan (bernard. mulligan@ec. europa. eu) Personalized Medicine unit (F 5) Head of unit: Patrik Kolar (patrik. kolar@ec. europa. eu) Deputy Head of unit: Irene Norstedt (irene. norstedt@ec. europa. eu) Horizontal Aspects unit (F 1) Head of unit: Stéphane Hogan (stephane. hogan@ec. europa. eu) Administration & Finance unit (F 6) Head of unit: Georgios Zisimatos (georgios. zisimatos@ec. europa. eu) 3/16/2018 25

What is Horizon 2020 3/16/2018 26

THANK YOU FOR YOUR ATTENTION! Grigorij Kogan « Chronic Diseases » Unit F-2 Medical Research Directorate F « Health » DG Research and Innovation European Commission grigorij. kogan@ec. europa. eu 3/16/2018 27